National Cancer Insitute Director's Address
New Discoveries in Treating Women's Cancer Reported at ASCO Meeting
Optimal Timing of Breast Cancer Surgery Within Menstrual Cycle
Phase I Study Results for Pegylated Megakaryocyte Growth And Development Factor, A New Platelet Growth Factor
Phase I Study Results for Thrombopoietin, A New Cytokine

Progression-Free Survival Not Tied to R-CHOP Dose Density

Sep 21, 2011 - There is no significant difference in progression-free survival for patients with indolent B-cell lymphoma treated with rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone along with granulocyte colony-stimulating factor every three weeks or every two weeks, according to a study published online Sept. 19 in the Journal of Clinical Oncology.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información